Exhibit 99.1 Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates • Net product revenue of $42.1M in 4Q and $50.7M for the year • New England Journal of Medicine publication of the use of B-VEC eyedrop formulation • Reached alignment with FDA to enable approval of B-VEC eyedrop formulation for the treatment of lesions in the eye of DEB patients • First patient dosed in Phase 1 KB408 trial for the treatment of AATD; five active clinical trials in 2024 • ...

现金及投资情况 - 公司在2023年12月31日拥有约5.322亿美元的现金、现金等价物和短期投资[311] 投资策略 - 公司的投资目标是在最大化收入的同时保持本金，以降低市场风险[311] 外汇风险 - 公司在欧洲和澳大利亚设立业务，并持有瑞士法郎、欧元和澳大利亚元的现金，面临外汇风险[311]

Krystal Biotech Inc. (NASDAQ:KRYS) Q3 2023 Earnings Conference Call November 6, 2023 8:30 AM ET Company Participants Meg Dodge - VP, Investor Relations & Corporate Communications Krish Krishnan - Chairman & Chief Executive Officer Suma Krishnan - President, Research & Development Kathryn Romano - EVP & Chief Accounting Officer Conference Call Participants Robert Finke - Guggenheim Partners Alec Stranahan - Bank of America Merrill Lynch Ritu Baral - Cowen Carly Kenselaar - Citigroup Dae Gon Ha - Stifel Tim ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________ FORM 10-Q _____________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38210 _________ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________ FORM 10-Q _____________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38210 ______________ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________ FORM 10-Q _____________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38210 _____________ ...

Developing Genetic Medicines for Rare Diseases Februar y 2023 © Copyright 2023 Krystal Biotech, Inc. All rights reserved. Forward Looking Statements ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________________________________ FORM 10-K _______________________________________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO ...